Skip to content

Abstract B036: Systematic Germline and Tumor Genomic Analysis for Gene Discovery in Familial Pancreatic Cancer

Sep 2026 · Cancer Research · 0 citations

TL;DR

A systematic discovery pipeline focused on families with multiple affected individuals, leveraging familial segregation and matched tumor analysis to identify novel hereditary PDAC susceptibility genes, highlighting the complexity of hereditary PDAC and support continued genetic and functional evaluation of the prioritized candidate genes.

Abstract

Despite the identification of several pancreatic ductal adenocarcinoma (PDAC) predisposition genes, more than 75% of familial pancreatic cancer (FPC) families remain genetically unexplained. To address this, we developed a systematic discovery pipeline focused on families with multiple affected individuals, leveraging familial segregation and matched tumor analysis to identify novel hereditary PDAC susceptibility genes. We analyzed germline DNA sequencing samples from 1,628 individuals with PDAC, including 98 patients from 45 FPC families, defined in our study as at least two affected relatives on the same side of the family. Of the 1,628 patients, 462 individuals (65 related cases and 397 probands) were previously reported (Roberts et al., Cancer Discovery). Sequencing comprised 714 germline exome/genome datasets processed through a harmonized variant-calling pipeline (hg19) and 914 matched germline-tumor whole genomes analyzed using patient-level germline and somatic variant calling (hg38). FPC families with multiple affected individuals or available tumor sequencing comprised two discovery sets (Discovery-A1: 81 patients from 38 families; Discovery-A2: 17 patients from 7 families), while the remaining PDAC cohort was used for further candidate gene prioritization. Rare variants were defined as having an allele frequency <0.01 in ExAC v0.3 (hg19) or gnomAD v4.1.1 (hg38). Analyses were restricted to predicted loss-of-function variants, including frameshift indels, stop-gain/loss, and canonical splice-site variants. Discovery-A1 identified rare variants segregating among affected relatives in at least two FPC families. Discovery-A2 evaluated segregating variants in FPC families with matched tumor sequencing showing loss of heterozygosity (LOH) of the gene of interest. Candidate genes were subsequently evaluated in the independent PDAC cohort. Discovery-A1 identified 12 segregating variants in 9 genes among 24 affected individuals from 12 FPC families. Six variants each recurred in two unrelated families, while six additional genes harbored distinct segregating variants in two independent families. Discovery-A2 identified segregating variants in 8 genes among 7 families, with tumor LOH observed in 6 of the 8 genes. Together, these analyses prioritized 17 candidate genes: ALDOB, CCDC105, CRYL1, DNAH9, EME2, ITIH2, MAP3K6, PKHD1L1, RYR1, SETD4, SFXN2, TGFBR2, TNFRSF10B, WDR87, XPOT, ZNF528, and ZNF599. Variant recurrence and tumor LOH in the independent PDAC cohort further prioritized several candidate genes. Combining familial segregation with matched tumor analysis efficiently prioritized candidate hereditary PDAC genes from a large genomic resource. Although several promising candidates have emerged, none currently provides sufficient evidence to establish a causal role in FPC susceptibility. These findings highlight the complexity of hereditary PDAC and support continued genetic and functional evaluation of the prioritized candidate genes. Jingxiong Xu, Yael Goldberg, Amy Zhang, Alison P. Klein, Nicholas J. Roberts, George Zogopoulos, Spring Holter, Steven Gallinger, Roberts C. Grant. Systematic Germline and Tumor Genomic Analysis for Gene Discovery in Familial Pancreatic Cancer [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B036.

View source

Similar papers

Open access Aug 2026

Multi-ancestry sequencing analysis in 293,141 participants identifies predisposition DNA repair genes associated with HCC risk.

Rare variants in MSH6 and BRCA2 are significantly associated with increased HCC risk, revealing a previously unconfirmed role for DNA repair genes in HCC susceptibility across ancestrally diverse populations and may inform genetic risk stratification and surveillance strategies.

A. Garófalo, Perapa Chotiprasidhi, Josephine P. Johnson et al. · 0 citations
Open access Aug 2026

Comprehensive Genomic Profiling Reveals the Mutational Spectrum and Clinical Significance of BRCA1/2 and Other Cancer-Susceptibility Genes in Breast Cancer Patients from Southern Tunisia

This study investigated germline genetic variants in 165 Tunisian breast cancer patients using targeted next-generation sequencing of a multigene cancer panel to identify pathogenic or likely pathogenic variants in BRCA1 and BRCA2 genes and identified P/LPVs in other genes.

N. Ammous-Boukhris, Rania Abdelmaksoud-Dammak, W. Ben Kridis et al. · 0 citations
Open access Aug 2026

Exome-based cancer driver gene comprehensive testing can provide a genetic diagnosis for individuals with triple-negative breast cancer

Triple-negative breast cancer (TNBC) is characterized by aggressive behaviour, high tumor heterogeneity, and an increased likelihood of recurrence and early metastasis. These factors hinder successful treatment. Genetic diagnosis enables personalized clinical recommendations and treatment options. The objective of this...

D. Alzate, A. Y. Sánchez, Yovana Pacheco et al. · 0 citations
Open access Aug 2026

CHEK2 Germline Variants in Cancer Predisposition: Whole Genome Sequencing Results

Assessment of the role of germline CHEK2 variants in the development of different cancer types confirmed that CHEK2 c.470T>C is the most common variant in the patient group, and the contribution of this variant to hereditary cancer risk in the Russian population is modest.

M. Nemtsova, M. Makarova, Anastasiia M. Danishevich et al. · 0 citations
Open access Aug 2026

Targeted Germline Sequencing Identifies Ultra-Rare DDR Variants in High-Risk Prostate Cancer

High-risk and early-onset PCa is associated with rare germline DDR alterations, and expanded germline testing in younger patients is supported and potential relevance for precision oncology approaches is suggested.

Rawaz Rizgar, Hassan, Abdulkarim Y Karim et al. · 0 citations
Case report Open access Sep 2026

Familial Pancreatic Cancer Associated with a Shared BRIP1 Variant: Implications for Homologous Recombination Deficiency and Targeted Therapy

The occurrence of PDAC in a father and son whose tumors independently harbored the same BRIP1 p.K159E VUS in both tumors represents an unusual familial and molecular observation, and raises the hypothesis that this BRIP1 variant may warrant further investigation in the context of homologous recombination repair.

Nils Degrauwe, Giovanni Dei Tos, M. Trimech et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.